Abiosciences – Leader in Single-Cell and Spatial Multi-Omics Clinical Research Services, Invites You to Explore New Drug Trends in March
Abiosciences
Life Science Technology Developer
Exhibition Information
Booth
March 6-7, 2025 • Shanghai, China
NDC2025 Shanghai (Yangtze River Delta) New Drug Innovators Summit
Booth No.: A22
Company Profile
Abiosciences, founded in 2018, is a life science technology company with a global vision. It is committed to fully applying single-cell mechanism research platforms and bioinformatics big data/AI platforms to the diagnosis and treatment of major human diseases such as cancer. By leveraging its strong research capabilities, proprietary platforms, and data, it aims to create precise cellular maps of human diseases, identify breakthrough diagnostic and therapeutic targets, and develop disruptive treatment methods.
Focusing on the frontier technology of single-cell and spatial multi-omics, Abiosciences has established a comprehensive technical platform, including clinical research and translational medicine platforms.
In terms of clinical research, we have established a one-stop service platform covering experiment design, sample processing, data analysis, and data mining. The service team possesses top-tier technical expertise in the industry and has accumulated extensive project experience, handling more than 90% of human and mouse tissue types. With comprehensive instruments and equipment, as well as rigorous experimental operations, the team ensures the continuous production of high-quality data. The analysis team demonstrates strong algorithm development and application capabilities, providing professional and efficient services to clinical researchers and pharmaceutical R&D personnel. The platform’s service outcomes have been published in high-impact journals such as Cell, Nature, Science, Cancer Cell, and Nature Immunology.
In the field of translational medicine research, Abiosciences' subsidiary—Shanghai XingSai Biotechnology Co., Ltd.—fully utilizes technologies such as single-cell sequencing and AI to establish a target discovery platform and a drug candidate molecule development platform. They explore and mine innovative drug targets and develop novel tumor immunotherapy strategies. To date, they have discovered and validated multiple highly promising preclinical candidate compounds (PCCs) and filed several international patents.Gilead Sciences Inc., Zai Lab, Keymed Biosciences and other internationally renowned pharmaceutical companies have reached cooperation.
Swipe up and down to view the specific agenda
Host:
Gong YuanxiangPresident of Zhuhai Hengqin Haomai Technology Co., Ltd.
09:00-09:30
Trends and Opportunities in Innovative Drug Development in 2025
Wang XingliFosun Pharma, Executive President & Co-CEO of Innovative Drug Division
09:30-10:00
How Will CR Pharmaceutical Address the Uncertainty of 2025
Cui XingpinVice President, CR Pharmaceutical
10:00-10:30
Accelerate Innovation, Embrace the World, and Open a New Chapter of Growth
Xie XinChina Biopharmaceuticals, Executive Director, Senior Vice President
10:30-10:50
Coffee Break
10:50-11:20
Through AI and Big Data: Future Insights and Innovation Prospects in Biomedical R&D
Gong YuanxiangPresident of Zhuhai Hengqin Haomai Technology Co., Ltd.
11:20-12:00
Roundtable: Cooperation + Going Global, Pushing Chinese Innovation onto the World Stage
1. What are the impacts of the NewCo model's popularity on pharmaceutical R&D? What effects has it brought to China's innovative drug capital market?
2. Key Points for Choosing the Path of Product Pipeline Overseas Expansion
3. Project transfer overseas, newco, formulation export, and API export: What are the pain points and obstacles for each (e.g., economic cycles, trade protectionism, local competition, trust, etc.)?
Wang Jun Linko Pharmaceuticals, CSO (Host)
Zhao XiaolinLilly China Innovation Collaboration Center, Senior Advisor for External Innovation Collaboration
Cui HaifengJiMin Trust Group Shanghai JiYu Pharmaceuticals, VP&CSO
Cao FeiYing Shi Bio, Co-Founder/Chief Operating Officer
Wang Xinguang Shanghai Rui Shi Consulting Co., LTD ，GM Chief Strategical Advisor
12:00-13:30
Lunch
Host:
Zhou LiTianqin Biotech, Executive Vice President; Chairman of the Reproductive Toxicology Professional Committee of the Chinese Society of Toxicology
13:30-13:55
USP Quality Standards for Therapeutic Monoclonal Antibodies
Cen GuoshanUS Pharmacopeial Convention, Vice President and General Manager of Greater China
13:55-14:20
Research and Development of Tumor Immunotherapy Agonists and Multi-Antibody Prodrug Molecules
Jiang WeidongKangkang Bio, CEO
14:20-14:45
Organoids Advance New Drug Development
Xiao XinghuiDirector of Cancer Pharmacology Department, Cephei Biotech
14:45-15:10
Nonclinical Safety Evaluation Strategies and Case Studies for ADC Drugs
Zhou LiTianqin Biotech, Executive Vice President; Chairman of the Reproductive Toxicology Professional Committee of the Chinese Society of Toxicology
15:10-15:35
Extracellular Cleavage Linker Iteration Update for ADC
Cai JiaqiangYilian Biotechnology (Suzhou), Co-Founder, CSO
15:35-16:00
Frontier Exploration of Radiopharmaceuticals in Clinical Applications
Single WaveCEO of Suzhou Borui Chuanghe
16:00-16:25
Research Challenges and Application Prospects of Multispecific Antibody Drugs
High-TechImmunoArk, Founder, Chairman and CEO
16:25-16:50
Application of BioAI Models in the Early Research of Antibody Drugs
Liu JianghaiShengshi Junlian, Founder & General Manager
16:50-17:15
Pharmacodynamics Evaluation of XDC Drugs
Zhu Saijie Succession Pharmaceuticals, VP
17:15-17:40
The Epic Transformation of One-Click Large Model Writing for Any Pharmaceutical Development Report
Li XingBeijing Deep Intelligence Technology Co., Ltd., CEO
Host:
Hu YonghanCNOVA, CTO
09:00-09:30
From the Blossoms of JPM, Seeking Survival and Development Strategies for Biotech Startups: The Overseas Expansion Chapter
Cai XuejunFormer BMS, Global R&D Vice President
09:30-10:00
Advances in Small Molecule New Drugs
Hu YonghanCStone, CTO
10:00-10:30
Analysis of Key Factors in Clinical Development and Registration for Innovative Drugs Going Overseas
Shen XiaoHaisen Bio, Chief Medical Officer
10:30-10:50
Tea Break
10:50-11:20
Advances in Transdermal Delivery Technology and New Drug Development
Sheng XiaoxiaLeading Pharma, CEO
11:20-12:00
Roundtable Dialogue: Development Layout and Trends in Small Molecule Innovative Drug Research
Hu YonghanCStone, CTO (Host)
Zhang HanchengInnovent Biologics, Chairman & President
Cai XuejunFormer BMS, Global R&D Vice President
Sheng YanciHenlius, General Manager of Global Strategy and Project Management
Xiao ShenHaisen Bio, Chief Medical Officer
12:00-13:30
Lunch
High-Potential Pharmaceutical Enterprises Exhibition
Host:Chen Bozhou,Calithera Biosciences, Co-Founder and CEO
13:30-13:55
From Single-Cell Technology to Disruptive Therapeutic Strategies
Xu XuanhaoAbiosciences, Single-Cell Medical Scientist
13:55-14:20
Development of Innovative Drugs for Chronic Pain Based on the Concept of Multimodal Analgesia
Wang YouxinLidao Pharmaceuticals, Chairman and CEO
14:20-14:45
NPTXR: New First in class target receptor for platform therapy of Solid tumors
Chen BaizhouCalithera Biosciences, Co-Founder and CEO
14:45-15:10
EP4 Antagonist: Paving a New Path for Cartilage Regeneration in Osteoarthritis
Deng YongqiKaif Pharmaceutical, Founder & CEO
15:10-15:30
Coffee Break
15:30-15:55
Exploring the Etiology of Autoimmune Diseases to Develop New Curative Drugs
Guohuang FanAmephi Biotech, Chairman
15:55-16:20
From Best-in-Class to First-in-Class (Indication): Development Strategy for a Potent Dual Selective JAK Inhibitor
Shen WangVivaVision Bio, CEO
16:20-16:45
Development of IKZF1/3 Molecular Glue Degraders
Liwén ZhàoChaoyang Pharmaceutical, CEO
16:45-17:10
Innovative Drug Platform GlycoTDS™ Based on Polysaccharides and the Industrialization of Targeted Anticancer Drugs
Wang SiSuzhou Shengduo Likang Pharmaceutical Co., Ltd., Founder/CEO
Host:
Yang JianyunPharmaCircle
13:30-14:00
Going Global in Progress: Case Studies of SINOVAC Biotech's International Exploration and Cooperation with China's Biopharmaceutical Enterprises
Shao KeSinobiological Inc., Vice General Manager
14:00-14:30
Shanghai Pharmaceutical's Experience Sharing in Expanding Southeast Asia, Middle East and North Africa Markets
Yan JunGeneral Manager of Shanghai Pharmaceuticals International Business Division
14:30-15:00
Pharmaceutical Companies Going Global: The Role of the FDA and Regulatory Requirements
Wang YapingFormer FDA Review Expert; Bluebird Bio, CMO of Therapeutic Products
15:00-15:20
Tea Break
15:20-15:50
Quality Assurance and Regulatory Requirements for Innovative Drug Products Going Overseas
Du XinEglin Pharmaceuticals, CEO
15:50-16:20
Current Status and Opportunities in BD for the Biopharmaceutical Industry and Protein Degradation Field in Recent Years
Zhou FengHangzhou Hezheng Pharmaceutical, Chief Strategy Officer
16:20-16:50
Quality Management Strategies in Multinational and Multicenter Clinical Trials
Shi WeiweiChina Quality Head of Thermo Fisher Clinical Trials Division
16:50-17:30
Roundtable Dialogue: Opportunities and Challenges for Pharmaceutical Companies Going Global (Policy, Market, Clinical)
Cai XuejunFormer BMS, Global R&D Vice President (Moderator)
Yan JunGeneral Manager of Shanghai Pharmaceutical International Business Division
Zhou FengHangzhou Hezheng Pharmaceutical, Chief Strategy Officer
Du XinCEO of Eglin Pharmaceuticals
Shi WeiweiHead of Quality, China, Thermo Fisher Clinical Trials Division
Host:
Xing LiAbiosciences, CEO
09:00-09:25
Design of Lipid Nanocarriers and Their Exploration in RNA Drug Development
Zhang XueqingRongcan Bio, Chief Scientist
09:25-09:50
A Novel Small Nucleic Acid Delivery System: QTsome™
Lin JialiangHaichang Bio, Head of Delivery System Research and Development at the New Drug Research and Development Center
09:50-10:15
Crossing the CGT Original Innovation Death Valley through Open Innovation: A Case Study of Targeted Integration of Large Gene Fragments in Cell Therapy
Xie XuanhuiReindeer Bio, Chief Innovation and Investment Officer
10:15-10:35
Coffee Break
10:35-11:00
The Practice of AI in Efficiently Discovering Clinical Candidate Drugs
Xing LiAbiosciences, CEO
11:00-11:25
Key Points for IND Submission of Nucleic Acid Vaccines
Lu HangJIAYI Bio, CEO
11:25-11:50
Development of In vivo CAR-T Therapy Based on LNP-mRNA Technology
Hu RongkuanXingrui Pharmaceuticals, Chairman and CEO
11:50-12:15
The Impact of the Dawn of Commercialization on the Landscape of China's Innovative Drug Industry in the New Decade
Liu QianAstraZeneca China, General Manager of the Respiratory and Gastrointestinal Business Unit
12:15-13:30
Lunch
Host:
Liu GuozhuChenchen Pharmaceuticals, Founder & Chairman
13:30-13:55
Rational Design of Nucleic Acid Drug Sequences Sharing
Pan JuanEdding Pharma, Director of Preclinical Research and Development
13:55-14:20
Obesity/Weight-loss Drug Development (Proposed)
Jing ShuqianHongyun Hua Ning, Founder, Chairman and CEO
14:20-14:45
Case Study on the Identification of Semaglutide and Tirzepatide Impurities
Liu GuozhuChenchen Pharmaceuticals, Founder & Chairman
14:45-15:10
Research on AI-Based Protein Drug Design Methods and GLP-1 Peptide Drug Practice
Chen HaifengShanghai Jiao Tong University, Professor; Co-founder of Zhiyao Yuanchuang
15:10-15:35
Development of New Drugs Based on Survival Strategy Animal Toxin Peptides
Rong MingqiangPed Bio, Chairman
15:35-16:00
Stability Modification and Drug Metabolism Analysis Methods of FGF21 Analogues
Zhou ZhenxingDoer Biologics, Senior Director of Bioanalysis
16:00-16:25
Medical Concept Validation and Minimally Invasive Interventional Drug Delivery Technology Platform
Li YongyongTongji University, School of Medicine, Professor
Liu MingliPharmCube
09:00-09:30
Protein Degradation Dual Platform (GlueTacs®) Driven Tumor and Immunotherapy Drug Development
Xiaobao YangFounder, Chairman, and CEO of Signet Biotech
09:30-10:00
Global Progress in the Development of New Anti-Influenza Virus Drugs
Chen XiaoxinZhongsheng Ruichuang, Co-Founder, Director, President
10:00-10:30
Application of Experimental Design (DOE) in Quality Risk Assessment for Commercial Production Processes of Small Molecule Innovative Drugs: Development Workflow and Case Study Sharing
Liu JuntaoBeiGene, Director of Process Development
10:30-10:50
A Good Process is Important for Small Molecule New Drugs
Fu PengMuhon Chemical, CEO
10:50-11:20
Mitochondrial Uncouplers and Their Applications in the Field of Metabolic Diseases
Ma TianweiDean of JunShengTai Pharmaceutical Translational Science Academy
11:20-11:50
Pharmaceutical Considerations in the Clinical Translation of Small Molecule Innovative Drugs
Li YongguoJayPharm, Chairman & CSO
11:50-12:10
ACT001 Combined with Radiotherapy: A Breakthrough Treatment for Small Cell Lung Cancer Brain Metastases in China
Chen Yue Shangde Pharmaceutical, Founder & Chairman
12:10-13:30
Lunch
Host:
13:30-14:00
Current Status and Future Directions in Pain Management Drug Development
Chen BozhouCalithera Biosciences, Co-Founder and CEO
14:00-14:30
In-situ Neural Regeneration Technology of the Brain and Clinical Translation
Chen GongDirector of the Brain Repair Center, Jinan University; Founder and Chairman of NeuroX Biotech
14:30-15:00
Development and Challenges of Proteolysis Targeting Chimeras (PROTAC) Drugs
Zeng LiHepharma, CEO
15:00-15:30
Research on FLT3-ITD Inhibitor Resistance Mechanisms and Development of Innovative Targeted Intervention Strategies
Yang GuangNankai University, College of Pharmacy, Professor & Doctoral Supervisor
15:30-16:00
Progress in Anti-Aging Research and Opportunities for Clinical Innovation Drug Development
Zhang JianGeneral Manager of Jiangsu Lead Bio
16:00-16:30
Synthetic Lethal Drugs: Opportunities, Challenges, and Development Trends
Chen XuxingYouli Biologics, Founder, CEO